Identification

Name
Benazepril
Accession Number
DB00542  (APRD00063)
Type
Small Molecule
Groups
Approved, Investigational
Description

Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Structure
Thumb
Synonyms
  • Benazeprilum
External IDs
C09AA07 / CGS-14824A
Product Ingredients
IngredientUNIICASInChI Key
Benazepril HydrochlorideN1SN99T69T86541-74-4VPSRQEHTHIMDQM-FKLPMGAJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet10 mgOralAa Pharma Inc2007-05-15Not applicableCanada
BenazeprilTablet20 mgOralAa Pharma Inc2006-03-24Not applicableCanada
BenazeprilTablet5 mgOralAa Pharma Inc2007-05-15Not applicableCanada
LotensinTablet20 mg/1OralNovartis1991-06-252016-02-01Us
LotensinTablet40 mg/1OralPhysicians Total Care, Inc.1999-02-24Not applicableUs
LotensinTablet40 mg/1OralValidus Pharmaceuticals1991-06-21Not applicableUs
LotensinTablet40 mg/1OralNovartis1991-06-252016-01-01Us
LotensinTablet10 mg/1OralPhysicians Total Care, Inc.2003-11-04Not applicableUs
LotensinTablet5 mg/1OralValidus Pharmaceuticals1991-06-212017-09-01Us
LotensinTablet10 mg/1OralValidus Pharmaceuticals1991-06-21Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet20 mg/1OralStat Rx USA2010-02-02Not applicableUs65162 0753 10 nlmimage10 7a3a3d61
BenazeprilTablet, coated40 mg/1OralInternational Laboratories, Llc2013-09-19Not applicableUs00093 5127 01 nlmimage10 7c233e09
Benazepril HClTablet10 mg/1OralNorthwind Pharmaceuticals2016-06-23Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralUnit Dose Services2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralApotex Corporation2006-04-16Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-01Not applicableUs
Benazepril HydrochlorideTablet5 mg/1OralMajor2010-02-02Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralStat Rx USA2009-10-27Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralSt. Marys Medical Park Pharmacy2014-01-15Not applicableUs
International/Other Brands
Briem (Pierre Fabre (France)) / Cibacen (Novartis (Belgium, Philippines, Switzerland, Turkey), Meda (Denmark, Germany, Greece, Ireland, Italy, Netherlands, Spain)) / Cibacen WS / Cibacene (Meda (France))
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AmlobenzBenazepril Hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0339 01 nlmimage10 6d03b6bd
AmlobenzBenazepril Hydrochloride (20 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralRebel Distributors2010-04-19Not applicableUs55111 0341 01 nlmimage10 c238e107
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (40 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralMylan Pharmaceuticals2012-02-20Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (40 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralApotex Corporation2013-12-30Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (40 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralAurobindo Pharma2012-09-05Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralA S Medication Solutions2012-09-052017-06-20Us
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (20 mg/1) + Amlodipine besylate (10 mg/1)CapsuleOralTeva2007-05-18Not applicableUs00093 7373 01 nlmimage10 031b81cc
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (10 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralMylan Pharmaceuticals2012-02-20Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (20 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralActavis Pharma Company2010-10-13Not applicableUs
Amlodipine and Benazepril HydrochlorideBenazepril Hydrochloride (20 mg/1) + Amlodipine besylate (5 mg/1)CapsuleOralCitron Pharma LLC2012-09-05Not applicableUs
Categories
UNII
UDM7Q7QWP8
CAS number
86541-75-5
Weight
Average: 424.4895
Monoisotopic: 424.199822016
Chemical Formula
C24H28N2O5
InChI Key
XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
IUPAC Name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCC2=CC=CC=C2N(CC(O)=O)C1=O

Pharmacology

Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Structured Indications
Pharmacodynamics

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

Mechanism of action

Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.

Volume of distribution
Not Available
Protein binding

benazepril, 97%; benazeprilat, 95%

Metabolism

Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.

Route of elimination

Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.

Half life

10-11 hours

Clearance
  • 0.35 L/hr/kg [pediatric hypertensive patients receiving multiple daily doses of Benazepril hydrochloride 0.1 - 0.5 mg/kg]
  • 0.13 L/hr/kg [healthy adults receiving a single dose of 10 mg]
Toxicity

Most likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Benazepril Metabolism PathwayDrug metabolism
Benazepril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Benazepril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Benazepril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Benazepril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Benazepril is combined with Acemetacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Benazepril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Benazepril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Benazepril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Benazepril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Benazepril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Benazepril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Benazepril.Approved, Illicit, Investigational
AlprenololBenazepril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanBenazepril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Benazepril.Experimental, Investigational
AmifostineBenazepril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Benazepril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Benazepril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Benazepril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Benazepril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Benazepril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Benazepril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Benazepril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Benazepril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Benazepril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Benazepril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Benazepril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Benazepril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Benazepril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Benazepril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Benazepril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Benazepril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Benazepril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Benazepril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Benazepril.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Benazepril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Benazepril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Benazepril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Benazepril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.Withdrawn
AzathioprineBenazepril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Benazepril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benazepril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Benazepril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Benazepril.Experimental
BarbitalBarbital may increase the hypotensive activities of Benazepril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Benazepril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Benazepril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Benazepril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Benazepril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benazepril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Benzydamine.Approved
BepridilBenazepril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Benazepril.Approved
BethanidineBethanidine may increase the hypotensive activities of Benazepril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Benazepril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Benazepril.Experimental
BimatoprostBenazepril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Benazepril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Benazepril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Benazepril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Benazepril.Approved, Investigational
BQ-123Benazepril may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Benazepril is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Benazepril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Benazepril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Benazepril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Benazepril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Benazepril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benazepril.Approved, Investigational
BupranololBenazepril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Benazepril.Approved
CadralazineCadralazine may increase the hypotensive activities of Benazepril.Experimental
CafedrineBenazepril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Benazepril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Benazepril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Benazepril.Approved
CandoxatrilBenazepril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Captopril.Approved
CarbamazepineThe metabolism of Benazepril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Benazepril.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Benazepril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Benazepril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Benazepril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Benazepril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Benazepril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Celecoxib.Approved, Investigational
CeliprololBenazepril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Benazepril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Benazepril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benazepril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Benazepril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Benazepril is combined with Choline magnesium trisalicylate.Approved
CicletanineBenazepril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Benazepril.Approved, Investigational
CiprofloxacinBenazepril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Benazepril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Benazepril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Benazepril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonixin.Approved
CloranololBenazepril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Benazepril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Benazepril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Benazepril.Approved
CryptenamineBenazepril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Benazepril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.Approved
CyclopenthiazideBenazepril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Benazepril.Approved, Investigational, Vet Approved
CyclothiazideBenazepril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Benazepril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Benazepril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Benazepril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Benazepril.Approved, Investigational
DelaprilBenazepril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Benazepril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Benazepril.Investigational
DeserpidineBenazepril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Benazepril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Benazepril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Benazepril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Benazepril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Benazepril.Approved, Investigational
diethylnorspermineBenazepril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benazepril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Benazepril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Benazepril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benazepril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Benazepril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benazepril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Benazepril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Dipyridamole.Approved
DorzolamideBenazepril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Benazepril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Benazepril.Approved
DrospirenoneBenazepril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Droxicam.Approved
DuloxetineBenazepril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Benazepril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Benazepril.Approved
E-6201The risk or severity of adverse effects can be increased when Benazepril is combined with E-6201.Investigational
EfonidipineBenazepril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Enalapril.Approved, Vet Approved
EnalaprilatBenazepril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Benazepril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Benazepril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Benazepril.Approved
EpanololBenazepril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Benazepril.Approved
EpoprostenolBenazepril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benazepril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Benazepril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Benazepril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Benazepril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Benazepril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Benazepril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Benazepril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Benazepril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Benazepril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benazepril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Benazepril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Benazepril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Benazepril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Benazepril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.Approved
exisulindThe risk or severity of adverse effects can be increased when Benazepril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Benazepril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenbufen.Approved
FenoldopamBenazepril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Benazepril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Feprazone.Experimental
Ferulic acidBenazepril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benazepril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Benazepril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Benazepril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Benazepril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benazepril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Benazepril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Benazepril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Benazepril.Experimental
GuanabenzBenazepril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Benazepril.Approved
GuanazodineBenazepril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineBenazepril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Benazepril is combined with Guanfacine.Approved, Investigational
GuanoclorBenazepril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBenazepril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBenazepril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Benazepril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Benazepril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Benazepril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
HexamethoniumBenazepril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Benazepril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Benazepril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Benazepril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Vet Approved
HydroflumethiazideBenazepril may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Benazepril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Benazepril.Approved
IloprostIloprost may increase the hypotensive activities of Benazepril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Benazepril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Benazepril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Benazepril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Indapamide.Approved
IndenololBenazepril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Benazepril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Benazepril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Benazepril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Benazepril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Benazepril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Benazepril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Benazepril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Benazepril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Benazepril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Benazepril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Benazepril is combined with Labetalol.Approved
LacidipineBenazepril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Benazepril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostBenazepril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Benazepril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Benazepril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Benazepril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Benazepril.Approved, Investigational
LevodopaBenazepril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Benazepril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Benazepril.Approved
LinsidomineBenazepril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Benazepril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Benazepril.Experimental
LofexidineBenazepril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Benazepril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Benazepril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Lumiracoxib.Approved, Investigational
MacitentanBenazepril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Benazepril is combined with Magnesium salicylate.Approved
ManidipineBenazepril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Benazepril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Benazepril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Benazepril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Benazepril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Benazepril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Benazepril.Approved
MethoserpidineBenazepril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Benazepril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Benazepril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Benazepril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Benazepril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Benazepril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Benazepril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Benazepril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Benazepril.Approved, Investigational
MetyrosineBenazepril may increase the hypotensive activities of Metyrosine.Approved
MibefradilBenazepril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Benazepril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Benazepril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Benazepril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Benazepril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Benazepril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Benazepril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Benazepril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Benazepril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Benazepril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Benazepril.Approved, Investigational
MuzolimineBenazepril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Benazepril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Benazepril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Benazepril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Benazepril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Benazepril is combined with Naftifine.Approved
NaftopidilBenazepril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Benazepril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Benazepril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Benazepril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Benazepril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Benazepril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Benazepril is combined with Niflumic Acid.Approved
NiguldipineBenazepril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBenazepril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Benazepril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Benazepril.Approved
NitrendipineBenazepril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Benazepril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Benazepril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Benazepril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Benazepril.Approved
ObinutuzumabBenazepril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Benazepril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benazepril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Benazepril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.Approved
OmapatrilatBenazepril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Benazepril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Benazepril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxaprozin.Approved
OxprenololBenazepril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Benazepril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Benazepril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Benazepril is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Benazepril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Benazepril.Approved, Vet Approved
PentoliniumBenazepril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Benazepril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Benazepril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Benazepril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Benazepril.Approved
PhenoxybenzamineBenazepril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Benazepril.Withdrawn
PhentolamineBenazepril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Benazepril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Benazepril.Approved
PinacidilPinacidil may increase the hypotensive activities of Benazepril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Benazepril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benazepril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Benazepril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Benazepril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Benazepril.Withdrawn
Platelet Activating FactorBenazepril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideBenazepril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Benazepril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Benazepril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Benazepril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Benazepril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Benazepril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Benazepril is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Benazepril.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Benazepril is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.Approved
PTC299The risk or severity of adverse effects can be increased when Benazepril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Benazepril.Approved
QuinineQuinine may increase the hypotensive activities of Benazepril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Benazepril.Approved
RasagilineRasagiline may increase the hypotensive activities of Benazepril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benazepril.Approved
RemikirenRemikiren may increase the hypotensive activities of Benazepril.Approved
RescinnamineBenazepril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Benazepril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Benazepril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Benazepril.Approved
RisperidoneBenazepril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabBenazepril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benazepril.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Benazepril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Benazepril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Benazepril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Benazepril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benazepril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Benazepril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Benazepril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Benazepril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
SelexipagBenazepril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Benazepril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Benazepril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Benazepril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benazepril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Benazepril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Benazepril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Benazepril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benazepril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Benazepril.Approved, Investigational
SitaxentanBenazepril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Benazepril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Benazepril.Approved
Sodium phosphateBenazepril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.Approved
SpiraprilBenazepril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Benazepril.Approved
SRT501The risk or severity of adverse effects can be increased when Benazepril is combined with SRT501.Investigational
St. John's WortThe metabolism of Benazepril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Benazepril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benazepril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Benazepril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Benazepril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
TalinololBenazepril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Benazepril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benazepril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benazepril.Approved, Investigational
TemocaprilBenazepril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Benazepril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Benazepril is combined with Teriflunomide.Approved
TerlipressinBenazepril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineBenazepril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Benazepril.Approved, Investigational, Withdrawn
TheodrenalineBenazepril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Benazepril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benazepril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Benazepril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Tiaprofenic acid.Approved
TiboloneBenazepril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenBenazepril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Benazepril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Benazepril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Benazepril.Approved
TipranavirThe serum concentration of Benazepril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Benazepril.Approved
TolazolineBenazepril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benazepril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolmetin.Approved
TolonidineBenazepril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Benazepril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Benazepril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Benazepril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Benazepril.Approved
TranilastThe risk or severity of adverse effects can be increased when Benazepril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Benazepril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Benazepril.Approved
TravoprostTravoprost may increase the hypotensive activities of Benazepril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Benazepril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Benazepril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Benazepril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Benazepril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Benazepril is combined with Tribenoside.Experimental
TrichlormethiazideBenazepril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Benazepril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Benazepril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Benazepril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Benazepril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Benazepril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
UnoprostoneBenazepril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Benazepril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Benazepril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Benazepril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Benazepril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Benazepril.Approved, Investigational
VincamineBenazepril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBenazepril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideBenazepril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineBenazepril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Benazepril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Benazepril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilBenazepril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Benazepril is combined with Zomepirac.Withdrawn
Food Interactions
  • Benazepril may decrease the excretion of potassium. Salt um may increase the risk of hyperkalemia. substitutes containing potassi
  • Food slows absorption without decreasing the quantity absorbed.
  • Herbs that may attenuate the antihypertensive effect of benazepril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of benazepril.
  • Take without regard to meals.

References

Synthesis Reference

Wei-Hong Tseng, "ASYMMETRIC SYNTHESIS OF A KEY INTERMEDIATE FOR MAKING BENAZEPRIL AND ANALOGUES THEREOF." U.S. Patent US20020183515, issued December 05, 2002.

US20020183515
General References
  1. Chan KK, Buch A, Glazer RD, John VA, Barr WH: Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharm Res. 1994 Mar;11(3):432-7. [PubMed:8008712]
  2. De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB: Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. Diabete Metab. 1992 Jul-Aug;18(4):283-8. [PubMed:1459316]
  3. Gengo FM, Brady E: The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. [PubMed:1893642]
  4. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. [PubMed:16407508]
  5. Ishimitsu T, Akashiba A, Kameda T, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H: Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology (Carlton). 2007 Jun;12(3):294-8. [PubMed:17498126]
  6. MacNab M, Mallows S: Safety profile of benazepril in essential hypertension. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV33-7; discussion IV51-5. [PubMed:1893640]
  7. Szekacs B, Vajo Z, Dachman W: Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria. Acta Physiol Hung. 1996;84(4):361-7. [PubMed:9328608]
External Links
Human Metabolome Database
HMDB14682
KEGG Compound
C06843
PubChem Compound
5362124
PubChem Substance
46507884
ChemSpider
4514935
BindingDB
50021153
ChEBI
3011
ChEMBL
CHEMBL838
Therapeutic Targets Database
DAP000584
PharmGKB
PA448561
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Benazepril
ATC Codes
C09AA07 — BenazeprilC09BA07 — Benazepril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (237 KB)
MSDS
Download (57.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealhty1
1CompletedNot AvailableHealthy Volunteers7
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
2CompletedTreatmentAlport Syndrome1
2RecruitingTreatmentHenoch-Schoenlein Purpura Nephritis2
2TerminatedTreatmentHypertensive / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes2
3CompletedTreatmentHypertensive1
3RecruitingTreatmentRenal Alteration1
4CompletedTreatmentAlbuminuria1
4CompletedTreatmentAlbuminuria / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentDiabetes Mellitus (DM) / Hypertensive1
4CompletedTreatmentDiabetes / Hypertensive / Proteinuria1
4CompletedTreatmentHypertensive3
4CompletedTreatmentHypertensive / Left Ventricular Hypertrophy1
Not AvailableCompletedTreatmentMicroalbuminuria1
Not AvailableCompletedTreatmentRenal Function Disorder1
Not AvailableTerminatedTreatmentACE Inhibitor / Angiotensin II Type 1 Receptor Blockers / Dose-Response Relationship, Drug / Progression, Disease / Proteinuria / Renal Insufficiency,Chronic1
Not AvailableTerminatedTreatmentChronic Kidney Failure1
Not AvailableTerminatedTreatmentRenal Insufficiency,Chronic1

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Biokey inc
  • Genpharm inc
  • Huahai us inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
TabletOral10 mg
TabletOral10 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, coatedOral
Tablet, film coatedOral
TabletOral20 mg/1
TabletOral20 mg
TabletOral5 mg
TabletOral
Prices
Unit descriptionCostUnit
Lotensin 20 mg tablet2.08USD tablet
Lotensin 10 mg tablet2.0USD tablet
Lotensin 40 mg tablet2.0USD tablet
Lotensin 5 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Lotensin 20 mg Tablet1.14USD tablet
Benazepril hcl 10 mg tablet1.07USD tablet
Benazepril hcl 20 mg tablet1.07USD tablet
Benazepril hcl 40 mg tablet1.07USD tablet
Benazepril hcl 5 mg tablet1.07USD tablet
Lotensin 10 mg Tablet0.99USD tablet
Lotensin 5 mg Tablet0.84USD tablet
Apo-Benazepril 20 mg Tablet0.79USD tablet
Apo-Benazepril 10 mg Tablet0.69USD tablet
Apo-Benazepril 5 mg Tablet0.58USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6162802No1997-12-192017-12-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)148.5 °CPhysProp
water solubility2.229 mg/LNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP1.14ALOGPS
logP1.54ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.53ChemAxon
pKa (Strongest Basic)5.36ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.23 m3·mol-1ChemAxon
Polarizability44.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5732
Blood Brain Barrier-0.7082
Caco-2 permeable-0.7279
P-glycoprotein substrateSubstrate0.8466
P-glycoprotein inhibitor IInhibitor0.7426
P-glycoprotein inhibitor IINon-inhibitor0.7565
Renal organic cation transporterNon-inhibitor0.8239
CYP450 2C9 substrateNon-substrate0.7518
CYP450 2D6 substrateNon-substrate0.8563
CYP450 3A4 substrateSubstrate0.5632
CYP450 1A2 substrateNon-inhibitor0.8232
CYP450 2C9 inhibitorNon-inhibitor0.6875
CYP450 2D6 inhibitorNon-inhibitor0.8266
CYP450 2C19 inhibitorInhibitor0.5461
CYP450 3A4 inhibitorInhibitor0.5425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6038
Ames testNon AMES toxic0.8377
CarcinogenicityNon-carcinogens0.9435
BiodegradationNot ready biodegradable0.9713
Rat acute toxicity2.2082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Inhibitor0.6696
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ufu-0917700000-5f1f2ae9b1d7afc6eee5

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / Benzazepines / Aralkylamines / Fatty acid esters / Azepines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Amino acids / Lactams
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / Benzazepine / Alpha-amino acid or derivatives / Azepine / Fatty acid ester / Aralkylamine / Dicarboxylic acid or derivatives / Monocyclic benzene moiety / Fatty acyl
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboxylic acid monoester, ethyl ester, benzazepine (CHEBI:3011)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein complex binding
Specific Function
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name
MTHFR
Uniprot ID
P42898
Uniprot Name
Methylenetetrahydrofolate reductase
Molecular Weight
74595.895 Da
References
  1. Jiang S, Yu Y, Venners SA, Zhang Y, Xing H, Wang X, Xu X: Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7. doi: 10.1038/jhh.2010.50. Epub 2010 May 6. [PubMed:20445573]
  2. Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C, Wang X, Zhang Y, Peng S, Xu X: A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clin Exp Hypertens. 2005 Aug;27(6):509-21. [PubMed:16081343]
  3. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X: The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res. 2004;113(6):361-9. [PubMed:15226090]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34